ArticleActa dermato-venereologica2025

The Absence of Recent Systemic Therapy can be a Significant Risk Factor for Nemolizumab-associated Cutaneous Adverse Events in Patients with Prurigo Nodularis: A Single-centre Retrospective Study.

Yoshihito Mima et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.